ArticlePloS one2016
Resistance Surveillance in Candida albicans: A Five-Year Antifungal Susceptibility Evaluation in a Brazilian University Hospital.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Candida albicans-A systematic review to inform the World Health Organization Fungal Priority Pathogens List.Medical mycology · 2024Pooled it
- A simplified MALDI-TOF MS method for rapid fluconazole susceptibility testing inJournal of medical microbiology · 2026Article
- Diverse genetic pathways drive convergent fluconazole and caspofungin resistance phenotypes in Candida albicans.PloS one · 2026Article
- Antifungal Effects of Pterostilbene onJournal of fungi (Basel, Switzerland) · 2025Article
- Twenty-Year Course of Antifungal Resistance inJournal of fungi (Basel, Switzerland) · 2025Review
- Article
- Enhancing Antifungal Drug Discovery Through Co-Culture with AntarcticInternational journal of molecular sciences · 2024Article
- Sequential Induction of Drug Resistance and Characterization of an InitialJournal of fungi (Basel, Switzerland) · 2024Article
- Metal Nanoparticles to CombatMicroorganisms · 2023Review
- Emergence and circulation of azole-resistantFrontiers in cellular and infection microbiology · 2023Article
- Matrix-assisted laser desorption/ionisation-time of flight mass spectrometry azole susceptibility assessment in Candida and Aspergillus species.Memorias do Instituto Oswaldo Cruz · 2023Article
- Bioactive Coatings with Ag-Camphorimine Complexes to Prevent Surface Colonization by the Pathogenic YeastAntibiotics (Basel, Switzerland) · 2021Article
- Evaluation of Identification and Susceptibility forInternational journal of microbiology · 2021Article
- Ethnobotanical survey on plants used in the treatment of candidiasis in traditional markets of southern Benin.BMC complementary medicine and therapies · 2020Article
- Efficient identification of fungal antimicrobial principles by tandem MS and NMR database.Journal of food and drug analysis · 2019Article
- Detection of ERG11 point mutations in Iranian fluconazole-resistantCurrent medical mycology · 2019Article
- Preliminary study on the inhibitory effect of seaweedF1000Research · 2018Article
- Clinical and Microbiological Characteristics of Breakthrough Candidemia in Allogeneic Hematopoietic Stem Cell Transplant Recipients in a Japanese Hospital.Antimicrobial agents and chemotherapy · 2017Article
- Quantitation of ergosterol content and gene expression profile ofCurrent medical mycology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida albicans caused 44% of the overall candidemia episodes from 2006 to 2010 in our university tertiary care hospital. As different antifungal agents are used in therapy and also immunocompromised patients receive fluconazole prophylaxis in our institution, this study aimed to perform an antifungal susceptibility surveillance with the C.albicans bloodstream isolates and to characterize the fluconazole resistance in 2 non-blood C.albicans isolates by sequencing ERG11 gene. The study included 147 C. albicans bloodstream samples and 2 fluconazole resistant isolates: one from oral cavity (LIF 12560 fluconazole MIC: 8μg/mL) and one from esophageal cavity (LIF-E10 fluconazole MIC: 64μg/mL) of two different patients previously treated with oral fluconazole. The in vitro antifungal susceptibility to amphotericin B (AMB), 5-flucytosine (5FC), fluconazole (FLC), itraconazole (ITC), voriconazole (VRC), caspofungin (CASP) was performed by broth microdilution methodology recommended by the Clinical and Laboratory Standards Institute documents (M27-A3 and M27-S4, CLSI). All blood isolates were classified as susceptible according to CLSI guidelines for all evaluated antifungal agents (MIC range: 0,125-1.00 μg/mL for AMB, ≤0.125-1.00 μg/mL for 5FC, ≤0.125-0.5 μg/mL for FLC, ≤0.015-0.125 μg/mL for ITC, ≤0.015-0.06 μg/mL for VRC and ≤0.015-0.125 μg/mL for CASP). In this study, we also amplified and sequenced the ERG11 gene of LIF 12560 and LIF-E10 C.albicans isolates. Six mutations encoding distinct amino acid substitutions were found (E116D, T128K, E266D, A298V, G448V and G464S) and these mutations were previously described as associated with fluconazole resistance. Despite the large consumption of antifungals in our institution, resistant blood isolates were not found over the trial period. Further studies should be conducted, but it may be that the very prolonged direct contact with the oral antifungal agent administered to the patient from which was isolated LIF E-10, may have contributed to the development of resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.